According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventisï Taxotere (docetaxel), Bristol-Myers Squibbïs Paraplatin (carboplatin) and Eli Lillyïs Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.
This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.
Find out more about each product by clicking on respective links.
